Clinical Trial Update: OFS in Premenopausal Node+ Breast Cancer With Low Genomic Risk [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial evaluating ovarian function suppression in premenopausal, node-positive, estrogen receptor-positive, HER2-negative breast cancer with l…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Estrogen Receptor-positive Breast Cancer
• Node-positive Breast Cancer
• Premenopausal Breast Cancer

Drugs mentioned

• OFS (ovarian function suppression)

Snippet

Sponsor: Gangnam Severance Hospital | Conditions: Breast Cancer, Estrogen Receptor Positive Tumor | Phase 4 | Status: RECRUITING